CDH1 and breast carcinoma: Importantly, a recent seminal study using synthetic–lethal approaches in ILC breast cancer cell models with complete loss of E-cadherin expression suggested a specific therapeutic vulnerability to ROS1 inhibitors, providing the preclinical rationale for assessing ROS1 inhibitors, such as the licensed drug crizotinib, in ILCs with absent E-cadherin expression [16].